Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the limited objective evidence for using finasteride in women with alopecia, suggesting that it could be considered for those who don't benefit from minoxidil, but reports no new clinical results.

Finasteride improves hair growth and satisfaction in men with male pattern baldness but may cause sexual side effects.

In this case report, a 45-year-old man with treatment-resistant androgenetic alopecia experienced hair regrowth during oral bicalutamide treatment but also suffered adverse effects leading to discontinuation, highlighting the need for further studies on the safety and role of androgen receptor blockade in hair loss.

This narrative review concludes that long-term randomized controlled trials are needed to establish clear guidelines for testosterone therapy in women, given the lack of FDA-approved formulations and the variable quality of current treatments.

This literature review reports prevalent sexual dysfunctions, notably vaginal dryness, in women undergoing endocrine therapy for hormone-dependent breast cancer, highlighting the need for more multidisciplinary research and care to improve patient well-being.

In this study, AGA patients exhibited distinct lipidomic profiles and higher metabolic syndrome prevalence compared to controls, with certain lipids correlated to key AGA-related factors like DHT, PGD2, and TGF-β1.

This study concluded that dutasteride 0.5 mg/day improved hair growth in patients with androgenetic alopecia over six months but was associated with a higher prevalence of sexual dysfunction.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This review examines the sexual side effects of 5α-reductase inhibitors like finasteride, highlighting the increased risk of erectile dysfunction, libido reduction, and potential contribution to depression without new clinical findings.

This review outlines the major health consequences of anabolic-androgenic steroid abuse, with a focus on sexual and reproductive issues, and suggests management prioritizes cessation and relapse prevention due to lack of robust randomized trials.

In this study, the authors propose that drugs like trazodone and antipsychotics such as chlorpromazine, which can induce priapism, may help restore libido synaptic circuits, offering potential treatment for post-finasteride syndrome and post-SSRI sexual dysfunction.

This article reviews insights into the pathogenesis of primary cicatricial alopecias, such as lichen planopilaris, provided by emerging technologies, but it does not report new clinical results.

This review discusses the roles of various PLA2 enzymes in skin health and disease, highlighting potential pathways for future diagnosis and therapy, but it reports no new clinical results.

This review found that both finasteride and dutasteride are effective for treating hair loss in men with androgenetic alopecia, with dutasteride showing higher efficacy, but noted unclear clinical significance regarding potential negative impacts on reproduction, including possible sexual dysfunction and effects on spermatogenesis.

This review discusses the sexual side effects of finasteride and dutasteride, two 5-α-reductase inhibitors, and reports no new clinical findings while calling for further research into dosage differences.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

This retrospective pharmacovigilance study reviewed adverse event reports from 2004 to 2025 for drugs treating benign prostatic hyperplasia, identifying distinct safety signals for α1-blockers, 5ARIs, and PDE5I, including some potential new adverse events that require further investigation.

This study evaluated dermatologists' beliefs and counseling practices regarding finasteride's adverse effects, revealing that while 51% believed it could cause sexual side effects, fewer associated it with depression or infertility, highlighting a need for increased awareness and improved patient counseling.

This article discusses the need to investigate long-term effects of androgen manipulations independently of current levels, referencing Post-finasteride Syndrome as a relevant clinical example, and reports no new results.

This study found that training in a hypoxic chamber did not significantly impact skin features in overweight and obese women, though it did result in a notable reduction in body weight and BMI.

This study found that human meibomian glands differ significantly from free and hair-associated sebaceous glands in morphology and lipid composition, making them highly specialized holocrine glands.

The combination of finasteride and minoxidil is as safe and effective as minoxidil alone for improving hair growth in men.

Most women with excessive hair growth have PCOS; treatment varies and focuses on preventing new hair, with electrolysis as the only permanent removal method.

The researchers reported that nicotinic acid normalized excessive sebaceous lipogenesis without affecting basal lipogenesis and suggested potential anti-acne benefits.

The document concludes that treatments for female hair loss and excessive hair growth are temporary and not well-studied.

This article reviews assessment and management strategies for adolescent females with excessive hair growth and highlights the importance of evaluating potential androgen sources.

This review discusses the use of testosterone therapy for low libido in women, noting mixed evidence on breast cancer risk and a lack of long-term safety data.

This review found that 5α‐reductase inhibitors were associated with slightly increased rates of decreased libido, erectile and ejaculatory dysfunction, gynecomastia, and mood disorders compared to placebo, though their long-term effects remain unclear.

This review discusses the regulation of hair growth, causes of excessive androgen secretion, and current safe solutions for hyperandrogenism manifestations in women but reports no new clinical results.

This study observed that the osteopontin-derived peptide FOL-005 inhibited hair growth in human scalp skin models, contrary to its hair growth promotion in mice, supporting further clinical testing for excessive hair growth treatment.